MGMarianne Gex-Fabry

Marianne Gex-Fabry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marianne Gex-Fabry has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Chin Bin Eap

    Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland

    2 shared publications
  • Gilles Bertschy

    Department of Psychiatry and Mental Health, Strasbourg University Hospital, INSERM U1114, University of Strasbourg, F-67000 Strasbourg, France

    2 shared publications
  • Guido Bondolfi

    From the *Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Chêne-Bourg, Switzerland; and †Unit of Biochemistry and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Department of Psychiatry-CHUV, Cery Hospital, University of Lausanne, Prilly, Switzerland

    2 shared publications
  • Jean-Michel Aubry

    From the *Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Chêne-Bourg, Switzerland; and †Unit of Biochemistry and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Department of Psychiatry-CHUV, Cery Hospital, University of Lausanne, Prilly, Switzerland

    2 shared publications
  • Nicola Gervasoni

    From the *Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Chêne-Bourg, Switzerland; and †Unit of Biochemistry and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Department of Psychiatry-CHUV, Cery Hospital, University of Lausanne, Prilly, Switzerland

    2 shared publications
  • Beatrice Oneda

    From the *Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Chêne-Bourg, Switzerland; and †Unit of Biochemistry and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Department of Psychiatry-CHUV, Cery Hospital, University of Lausanne, Prilly, Switzerland

    1 shared publication

Latest Publications

  • CYP2D6 and ABCB1 Genetic Variability: Influence on Paroxetine Plasma Level and Therapeutic Response

    by Marianne Gex-Fabry, Chin B Eap, Beatrice Oneda, Nicola Gervasoni, Jean-Michel Aubry, Guido Bondolfi, Gilles Bertschy

    Paroxetine is characterized by large interindividual pharmacokinetic variability and heterogeneous response patterns. The present study investigates plasma concentration and therapeutic response to paroxetine for the influence of age, sex, and CYP2D6 and ABCB1 polymorphisms, the latter gene encoding for the permeability glycoprotein. Genotyping for CYP2D6 (alleles *3, *4, *5, *6, and *xN) and ABCB1 polymorphisms (61A>G, 2677G>T, and 3435C>T) was performed in 71 depressed patients who started 20 mg paroxetine per day and had plasma concentration measured after 2 weeks at a fixed dose. A dose increase to 30 mg per day was possible starting at week 2. For 63 patients, severity of depression (Montgomery-Åsberg Depression Rating Scale) was assessed at weeks 0, 2, and 4 and every 2 weeks thereafter until discontinuation. Persistent response was defined as 50% improvement from baseline score sustained from the first occurrence to study end point. Paroxetine concentration significantly differed between female and male patients (median, 28 versus 16 ng/mL; P = 0.001). Differences were not significant between CYP2D6 heterozygous and homozygous extensive metabolizers (median, 27 versus 22 ng/mL; P = 0.074) and between ABCB1 genotypes (P > 0.10). When considered in a multivariate model, CYP2D6 heterozygous extensive metabolizer phenotype (P = 0.062) and female gender (P = 0.001) predicted 1.3-fold and 1.6-fold higher paroxetine concentration, respectively, but fraction of explained variability was modest (21%). Frequency of persistent response at study end point did not significantly differ according to CYP2D6 heterozygous extensive metabolizer versus homozygous extensive metabolizer phenotype and ABCB1 polymorphisms in univariate analyses. After adjusting for age, sex, paroxetine concentration at week 2, and daily dose at study end point, ABCB1 genotype contributed to improving the model significantly for 61A>G (P = 0.043), but not 2677G>T (P = 0.068) and 3435C>T (P = 0.11). None of two poor metabolizers and four ultrarapid metabolizers showed persistent response to paroxetine. The hypothesis that permeability glycoprotein activity might be a relevant predictor of therapeutic response deserves to be further investigated while controlling for pharmacokinetic variability.


  • Time course of response to paroxetine: Influence of plasma level

    by Marianne Gex-Fabry, Nicola Gervasoni, Chin B. Eap, Jean-Michel Aubry, Guido Bondolfi, Gilles Bertschy